Parexel’s greenhouse gas reduction targets achieve SBTi validation

New Delhi: Parexel has received validation for its near-term greenhouse gas (GHG) reduction targets from the Science Based Targets initiative (SBTi). This validation places Parexel among the few clinical research organizations with officially recognized science-based targets.

The SBTi validation confirms Parexel’s ambitions to cut absolute Scope 1 GHG emissions by 42% by 2030, compared to 2022 levels. The company also pledges to continue sourcing 100% of its electricity from renewable sources through 2030 and to cut absolute Scope 3 GHG emissions by 25% over the same period.

CEO Peyton Howell highlighted, “Receiving SBTi validation for our near-term targets is an important milestone in our journey to achieving net-zero GHG emissions. Our environmental approach is comprehensive and multi-faceted and brings together team members from across Parexel. Together we are maximizing our industry partnerships and engaging our supply chain to collectively reduce the environmental impacts from our operations and contribute to a healthier planet.”

In alignment with its net-zero ambitions, Parexel is already making strides towards its 2025 goals. These include increasing its presence in green-certified buildings, encouraging sustainable travel to reduce emissions, ensuring that 100% of purchased electricity comes from renewable sources, and integrating green practices in clinical trials. The company’s 2023 ESG Report underscores these initiatives and reaffirms Parexel’s commitment to patient-centric operations and environmental stewardship under its With Heart™ ethos.